Alvoceva

Alvoceva Indications/Uses

erlotinib

Manufacturer:

Remedica

Distributor:

Zuellig Pharma
Full Prescribing Info
Indications/Uses
Non-Small Cell Lung Cancer (NSCLC): ALVOCEVA is indicated for the first-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.
ALVOCEVA is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy.
ALVOCEVA is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
When prescribing ALVOCEVA, factors associated with prolonged survival should be taken into account.
No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC negative tumours (see Pharmacology: Pharmacodynamics under Actions).
Pancreatic cancer: ALVOCEVA in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
When prescribing ALVOCEVA, factors associated with prolonged survival should be taken into account (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
No survival advantage could be shown for patients with locally advanced disease.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in